思路迪医药股份：恩维达补充申请获国家药监局正式受理

Core Viewpoint - The company has received acceptance from the National Medical Products Administration (NMPA) for the regular approval of its drug, Envita (generic name: Envolimab injection), which was previously conditionally approved [1] Group 1 - The drug Envita is now transitioning from conditional approval to regular approval in the domestic market [1] - The application for regular approval was submitted by Sichuan Silu Kangrui Pharmaceutical Co., Ltd., a subsidiary of the company [1] - The acceptance number for the application is CYSB2600056, with the application specification being 200mg (1.0ml) per bottle [1]